GlassScriptPhysician profile
Charles H Debusk
NPI 1780665745
$5,076.54
in general payments reported to CMS, 2019-2025
26 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $475 · 2021: $811 · 2022: $287 · 2023: $875 · 2024: $498 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,881.92 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $934.85 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $624.56 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $527.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.64 | 2019-2024 | Xifaxan |
| Pfizer INC. | $203.83 | 2019-2021 | |
| Mylan Specialty L.P. | $153.02 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.30 | 2019-2021 | |
| Abbvie INC. | $89.14 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $69.94 | 2021-2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $23.31 | 2023 | Voquezna |
| Lundbeck LLC | $22.86 | 2023 | Rexulti |
| Genentech USA, INC. | $20.74 | 2019 | |
| Abbott Laboratories | $19.86 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.42 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $17.54 | 2022 | |
| Corium, LLC | $16.46 | 2023 | Adlarity |
| Neurocrine Biosciences, INC. | $15.28 | 2024 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $14.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.09 | 2024 | Rexulti |
| Lilly USA, LLC | $12.96 | 2019 | |
| Eisai INC. | $12.61 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Debusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.